AstraZeneca has entered into a strategic collaboration and licensing agreement with Insitro, a privately held artificial intelligence (AI) therapeutics company based in San Francisco, in a deal valued at up to $1.5 billion. The partnership aims to leverage AI to identify new drug targets and expedite the development of therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease, as well as cardiovascular conditions.
Under the agreement, Insitro will receive $40 million upfront and is eligible for potential development and commercial milestone payments totaling around $1.5 billion, in addition to royalties on future global sales. The move reflects growing investment by major pharmaceutical companies in AI technologies to enhance drug discovery and development processes.
AstraZeneca, a Cambridge-based FTSE 100 company with an approximate market value of £191 billion, generates over 20% of its annual product revenue—about $58.6 billion—from cardiovascular, renal, and metabolic treatments. The company was formed in 1999 through the merger of the British firm Zeneca and the Swedish company Astra. In 2026, AstraZeneca expanded its market presence with a direct listing on the US stock market, complementing its existing listings in London and Stockholm. Following the announcement of the deal, AstraZeneca’s shares closed up 3.24% at £126.98 on the London Stock Exchange.
Sir Pascal Soriot, AstraZeneca’s chief executive, has expressed a positive outlook on AI’s role in the pharmaceutical industry, stating that AI tools are expected to improve productivity rather than eliminate jobs. He highlighted that AI can enhance research efficiency by enabling faster and higher-quality drug development.
Sharon Barr, head of biopharmaceuticals research and development at AstraZeneca, emphasized the complexity of disease biology and the critical nature of selecting appropriate targets in research. She described the partnership as part of AstraZeneca’s commitment to harnessing advanced AI technology to address the biological and genetic drivers of diseases.
Insitro was founded in 2018 by Daphne Koller, a specialist in machine learning. Last year, Insitro secured a separate partnership with Eli Lilly, a major US pharmaceutical company known for its diabetes and weight-loss drug Mounjaro. Koller noted that integrating large and complex datasets through AI could unlock new genetic insights and expand the potential for drug discovery.
The deal also highlights the emergence of a UK-based AI and life sciences cluster centered around London’s King’s Cross area, known as the Knowledge Quarter. This hub includes significant investments from companies such as AstraZeneca, GSK, and Boehringer Ingelheim, the latter committing £150 million to establish an AI and machine learning center there.
Industry analysts have forecast that global spending on AI-driven research and development could reach between $30 billion and $40 billion by 2040, underscoring the growing role of AI technology in shaping the future of pharmaceutical innovation.